Special Issue

Drug Targets and Associated Therapeutic Treatments for Parkinson's Disease

Message from the Guest Editor

Parkinson's disease (PD) is multifactorial age-related brain disease characterized by bradykinesia, fatigue, irregular blood pressure and major muscle-stiffness-associated difficulties. Despite extensive research, there is no cure for PD. To make scientific advances regarding therapeutic discoveries and mechanistic approaches to determining the basis of PD progression, PD modeling is a critical step. Currently, available cellular and genetic rodent models remain inefficient. For example, iPSC-based disease modeling and iPSC (induced pluripotent stem cell)-derived neurons (iNs) are not mature enough to recapitulate age-related pathological events, which instead require tools that can accelerate iNs maturation. In a different study, a disease-causing agent extracted from the human brain, supplemented with an in vitro growth media to induce PD pathogenesis, was proven to be a powerful approach to studying pathogen-specific disease induction, which is rapid and pathogen-species-specific; however, it does not eventually mimic the progressive manner of disease.

Guest Editor

Dr. Brijesh Kumar Singh
Columbia University Irving Medical Center, New York, NY, USA

Deadline for manuscript submissions

closed (30 November 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/159669

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).